ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
NeuroSense Therapeutics Ltd

NeuroSense Therapeutics Ltd (NRSN)

1.048
-0.0699
( -6.25% )
Updated: 05:51:03
Advanced chart

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.048
Bid
1.04
Offer
1.05
Volume
129,947
1.00 Day's Range 1.12
0.512 52 Week Range 2.33
Market Cap
Previous Close
1.1179
Open
1.12
Last Trade
200
@
1.048
Last Trade Time
05:48:37
Financial Volume
US$ 135,116
VWAP
1.0398
Average Volume (3m)
300,089
Shares Outstanding
19,470,000
Dividend Yield
-
PE Ratio
-0.98
Earnings Per Share (EPS)
-0.58
Revenue
-
Net Profit
-11.28M

About NeuroSense Therapeutics Ltd

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among... NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Herzliya, Center, Isr
Founded
-
NeuroSense Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NRSN. The last closing price for NeuroSense Therapeutics was US$1.12. Over the last year, NeuroSense Therapeutics shares have traded in a share price range of US$ 0.512 to US$ 2.33.

NeuroSense Therapeutics currently has 19,470,000 shares in issue. The market capitalisation of NeuroSense Therapeutics is US$21.77 million. NeuroSense Therapeutics has a price to earnings ratio (PE ratio) of -0.98.

NRSN Latest News

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement PR Newswire CAMBRIDGE, Mass., Jan. 6, 2025 NeuroSense in Compliance with all Nasdaq Listing RequirementsCAMBRIDGE, Mass...

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS PR Newswire CAMBRIDGE, Mass., Dec. 23, 2024 Binding Term Sheet with a leading global pharmaceutical company includes a...

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., Dec. 18, 2024 CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics...

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC PR Newswire CAMBRIDGE, Mass., Dec. 11, 2024 The Type C meeting with the FDA, combined with the recent 18-month Phase...

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS PR Newswire CAMBRIDGE, Mass., Dec. 4, 2024 In participants who...

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price PR Newswire CAMBRIDGE, Mass., Dec. 2, 2024 CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- NeuroSense...

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND PR Newswire CAMBRIDGE, Mass., Nov. 21, 2024 CAMBRIDGE, Mass., Nov. 21, 2024 /PRNewswire/ -- NeuroSense...

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission PR Newswire CAMBRIDGE, Mass., Oct. 28, 2024 Meeting discussion to focus on finalizing Phase 3 study design...

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients PR Newswire CAMBRIDGE, Mass., Oct. 24, 2024 Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE...

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates PR Newswire CAMBRIDGE, Mass., Oct. 15, 2024 Dossier submission planned...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.132-11.1864406781.181.289911121281.18015977CS
40.13815.16483516480.911.420.814836491.20131769CS
12-0.092-8.07017543861.141.420.83000891.16372939CS
260.10310.89947089950.9451.4550.5122983851.0081475CS
520.22927.96092796090.8192.330.5122772811.19369226CS
156-1.512-59.06252.568.180.49851803.38922595CS
260-3.502-76.9670329674.558.180.49687693.38781563CS

NRSN - Frequently Asked Questions (FAQ)

What is the current NeuroSense Therapeutics share price?
The current share price of NeuroSense Therapeutics is US$ 1.048
How many NeuroSense Therapeutics shares are in issue?
NeuroSense Therapeutics has 19,470,000 shares in issue
What is the market cap of NeuroSense Therapeutics?
The market capitalisation of NeuroSense Therapeutics is USD 21.77M
What is the 1 year trading range for NeuroSense Therapeutics share price?
NeuroSense Therapeutics has traded in the range of US$ 0.512 to US$ 2.33 during the past year
What is the PE ratio of NeuroSense Therapeutics?
The price to earnings ratio of NeuroSense Therapeutics is -0.98
What is the reporting currency for NeuroSense Therapeutics?
NeuroSense Therapeutics reports financial results in USD
What is the latest annual profit for NeuroSense Therapeutics?
The latest annual profit of NeuroSense Therapeutics is USD -11.28M
What is the registered address of NeuroSense Therapeutics?
The registered address for NeuroSense Therapeutics is MEDINAT HA-YEHUDIM STREET, 85, HERZLIYA, CENTER
What is the NeuroSense Therapeutics website address?
The website address for NeuroSense Therapeutics is www.neurosense-tx.com
Which industry sector does NeuroSense Therapeutics operate in?
NeuroSense Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DATSDatChat Inc
US$ 5.67
(76.64%)
142.23M
SPISPI Energy Company Ltd
US$ 1.045
(67.23%)
46.02M
CDTConduit Pharmaceuticals Inc
US$ 0.1301
(58.66%)
1.02B
VMARVision Marine Technologies Inc
US$ 2.31
(51.97%)
164.59M
GLXGGalaxy Payroll Group Ltd
US$ 1.40
(48.94%)
45.16M
IGMSIGM Biosciences Inc
US$ 2.15
(-65.32%)
4.63M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.755
(-54.30%)
2.02M
AIFUAIX Inc
US$ 0.3886
(-51.73%)
5.74M
XTIAXTI Aerospace Inc
US$ 7.04
(-44.24%)
4.95M
MODVModivCare Inc
US$ 7.00
(-43.96%)
1.53M
CDTConduit Pharmaceuticals Inc
US$ 0.13
(58.54%)
1.02B
VMARVision Marine Technologies Inc
US$ 2.315
(52.30%)
164.59M
DATSDatChat Inc
US$ 5.6401
(75.70%)
142.24M
NVDANVIDIA Corporation
US$ 136.5799
(-2.52%)
139.63M
RGTIRigetti Computing Inc
US$ 9.6386
(-4.00%)
138.19M

NRSN Financials

Financials

NRSN Discussion

View Posts
runncoach runncoach 9 minutes ago
If the company has to do another bridge money raise until a partnership, the recent filings of the last money raise likely show the reason the price remains so low IMO. The "most favored nations" clause tends to cap the share prices. That's besides the millions of warrant shares. Hopefully a buck and change holds.
👍️0
runncoach runncoach 24 minutes ago
Folks should be careful. If they don't get things finalized we could be looking at a reverse split. Partnerships don't always work out. Regardless, no sales in 2025 but hopefully they launch the P3 this summer as they project.
👍️0
johnhancoque johnhancoque 3 hours ago
Just gained nasdaq compliance and now threatening it. If anything, this is an emberassing complication for the ceo. Something needs to change here because the hedge funds are clearly in violation of manipulating the share price. The market cap is only 19 million. The ceo needs to up his game and get some positive pr happening or these guys will continue to manipulate the share price every day
👍️0
johnhancoque johnhancoque 3 weeks ago
Um...when was it approved? Blockbuster status won't be known until it's selling around the world, which won't be hard now with Big Pharma backing them. Your understanding of bios is very limited. Widen your horizons and stop wasting your time here as what you post makes very little sense anyways
👍️0
runncoach runncoach 3 weeks ago
Must have not been blockbuster, eh?
👍️0
johnhancoque johnhancoque 3 weeks ago
https://finance.yahoo.com/news/neurosense-therapeutics-enters-binding-term-140000065.html
👍️0
johnhancoque johnhancoque 3 weeks ago
Nobody claims a multibillion dollar partnership. Read the headlines. They are in discussions with several multi- billion dollar companies for partnerships. Also, they could have done a large public offering to keep the lights on as they are nasdaq listed. Instead the ceo chose to do a private placement and buy 5 million worth. The partnerships are for funding the continued trials and I know alot about how things work with pharma as I've been trading bios 20 years. The data is impressive and worth Billions and as the market catches on expect significant rises in the share price
👍️0
runncoach runncoach 3 weeks ago
How much do you think a P3 cost? That's why so little leverage. Why didn't they already get a partnership they've talked about for 4 months? It's not easy when you don't have cash. It's not going to be a multi billion partnership that I've seen some posting about. Ceo kept them listed and gave a couple months breathing room. Congrats to him
👍️0
johnhancoque johnhancoque 3 weeks ago
Right. You believe he did it to keep the lights on when he could have done a public offering for alot more. Instead, he spent 5 million of his own money suggesting he has faith in a very large partnership. Your way of thinking is twisted. No need reply again
👍️0
runncoach runncoach 3 weeks ago
I'm suggesting he bought to keep the company's listing and float the company til they find funding since they can't fund a P3 trial. It's not a strong position to negotiate from. I don't think I'm saying anything controversial or that isn't common sense at this point. I expect them to find something and then there will be a very long wait
👍️0
johnhancoque johnhancoque 3 weeks ago
You're suggesting the ceo bought 5 million worth of stock this month well above market value because he may not succeed in finding a partner? That sounds ridiculous buddy. It's more likely he is very confident in finding a partnership or is in the final stages so he bought 5 million worth. Your understanding of how insiders buys shares is out to bloody lunch. Hardly anyone would spend 5 million on a single stock without a near sure bet let alone a ceo of a publicly traded company
👍️0
johnhancoque johnhancoque 3 weeks ago
A ceo who had no faith in a partnership sure as he'll wouldn't pony up 5 million bucks if there was nothing in the works. Don't miss the forest for the trees. He bought 5 million worth because a partnership is in the works.
Smh
👍️0
runncoach runncoach 3 weeks ago
Been here long before you. Ceo ponied up money to meet Nasdaq requirements. Stock got shorted down so the "raise" price would look better.

Doesn't take a genius to realize not having the cash to even make it to the start of launching a P3 next summer isn't negotiating from a position of strength. If they don't get a partnership there would have to be a very unfavorable money raise to launch the trial. Between a rock and a hard place as far as negotiating.

Let's hope they get a partnership on favorable terms and a nice spike before the stock pulls back with the markets realizing another 12+ months til Canadian news and much longer than that for US.
👍️0
johnhancoque johnhancoque 3 weeks ago
So now and ceo who buys 5 million worth of stock isn't a good sign, it's a bad sign of a pump? Where do you guys come from, really?
Even with good news you shorts twist things unrecognizable. Truly unbelievable
The ceo bought 5 million worth 30% above the then market price. They don't need cash they need a partnership which they will have no problem finding and are in discussions right now with several Big Pharmas. Drugs like this don't go unnoticed long with Big pharma sniffing around. Just sell and get lost because your comments are useless to the investing community
👍️0
runncoach runncoach 3 weeks ago
Was wondering about the pump.

Folks will soon learn you don't get billion dollar partnerships when the CEO is having to buy stock to keep the lights on I'm afraid. Give me 3 bucks and I'll sit this one out for a while.
👍️0
johnhancoque johnhancoque 3 weeks ago
$7.50 Cantor price target 🥱👀
👍️0
runncoach runncoach 3 weeks ago
Not immediately it won't, no. Not in a price sustainable way that is. I own shares but will sell any significant spikes and buy back lower to hold long term
👍️0
johnhancoque johnhancoque 3 weeks ago
You don't understand. A partnership with BP takes NRSN to the next level no looking back. Once a partnership is announced with a large upfront payment, there will be no looking back for this company, ever. It will be bought by BIg Pharma long before p3 results. Easy to manufacture and worldwide protection until 2044
👍️0
runncoach runncoach 3 weeks ago
The problem is there is a large number of warrant shares available that will keep a lid on the share price after any spikes. Company has low funds considering it has yet to begin their P3. Sales are 2-3 years away at the least. Details of any partnership will be very important concerning future potential money raises. Sell significant spikes is my advice because folks sitting on warrants likely will. JMHO
👍️0
johnhancoque johnhancoque 3 weeks ago
$9.25 price target. Partnership news looks imminent. Only 25 million market cap has 400% to run at a minimum here
👍️0
johnhancoque johnhancoque 3 weeks ago
CEO bought 5 million worth and no matter how you spin that it will always be a boon for the company and shareholders. Regardless of what you say, any ceo who puts up 5 million bucks and above market for that matter says everything about where the sp is headed nearterm and speaks volumes about the confidence he has in his company and the data. Simple as that!
👍️0
McMagyar McMagyar 3 weeks ago
Except
The value would have already rocketed well past $1.25.. with so few shares out.. and after the news hit, the company could have raised the same amount of money by issuing fewer shares, less dilution, shares more valuable.. now only one shareholder benefits from knowing the good news.. sure looks like a shareholder lawsuit to me.. greed sucks.. maybe the other shareholders will let it go.. maybe they won't..
You can't control what happens, but you can control with whom you do bizness..
Thx Barrister.. wise words
👍️0
johnhancoque johnhancoque 3 weeks ago
All that matters is he bought 5 million shares @ $1.25 and the share price is about to rocket hard. Analysts price targets north of $12.00
👍️0
McMagyar McMagyar 3 weeks ago
This smells a lot like stealing to me..
All the other shareholders got diluted.. while the sole stock buyer of issuance becomes kazillionairre.. sounds like an attorney would want to know what the shareholder who bought all this stock knew.. and why the offering wasn't made to other shareholders?
👍️0
johnhancoque johnhancoque 3 weeks ago
Insider trading doesn't mean insiders can't buy shares or participate in offerings. There are however windows they have to abide by and if a significant partnership is announced in January they are well within their time to buy shares
👍️0
johnhancoque johnhancoque 3 weeks ago
Insider trading doesn't mean insiders can't buy shares or participate in offerings. There are however windows they have to abide by and if a significant partnership is announced in January they are well within their time to buy shares
👍️0
runncoach runncoach 4 weeks ago
That would look quite a bit like inside trading if they did that the next couple months. Trust me I hope so but doesn't look good to me.
👍️0
johnhancoque johnhancoque 4 weeks ago
$25.00 with partnership and large upfront payment
👍️0
johnhancoque johnhancoque 4 weeks ago
Um....he sold himself the last offering because there is a multi Billion dollar partnership about to be signed
👍 1
McMagyar McMagyar 1 month ago
It was a money raise to one guy.. total bullshit. Thief
👍️0
runncoach runncoach 1 month ago
The issue to me is the stock was sold down the last 2 or 3 weeks on "no news" and then we get a low price money raise. Doesn't look good
👍️0
McMagyar McMagyar 1 month ago
Co issues 12,000,000 share rights to one guy right before good news hits?  What a legal Scally wag.. what's to stop him from issuing himself another 10,000,000?  Know them but their greed.
What a crock
👍️0
runncoach runncoach 1 month ago
Today's PR would certainly lead one to believe no partnership type of completion until next year at the earliest IMO
👍️0
runncoach runncoach 1 month ago
Just under 21 million
👍️0
BurgerKing82 BurgerKing82 1 month ago
What's OS now?
👍️0
runncoach runncoach 4 months ago
From this evening's 6K. No idea if it's BS or not.
NeuroSense Therapeutics Ltd. (the Company) hereby reports that it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership for the development and commercialization of its lead drug candidate, PrimeC, for the treatment of Amyotrophic Lateral Sclerosis (ALS).



These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments and royalty payments as part of an agreement. NeuroSense anticipates receiving terms from these discussions in Q4 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what would be the final terms, if any, or that a definitive agreement will be reached.
👍️0
runncoach runncoach 5 months ago
Money raise with .75 warrants attached fyi. Now we know why the price has remained so low IMO
👍️0
vein vein 6 months ago
Thanks much for the insight !
👍️0
runncoach runncoach 6 months ago
Who knows? Unless you are trading the stock, real results are a long ways off IMO and that can lead to opportunity cost. If it's a small percentage of a speculative portfolio the current price probably isn't bad. Just depends on your patience level
👍️0
vein vein 6 months ago
Why the sell off ?? Thanks in advance!
👍️0
vein vein 6 months ago
Seems like a decent entry ?
👍️0
runncoach runncoach 6 months ago
The data is good but they'll have to raise money for a P3 so these guys are still a ways off IMO. They've mentioned a potential Biogen partnership last year yet here we stand. I do believe the drug is safe and has a real chance. Timing is everything.
👍️0
vein vein 6 months ago
Time to buy now ??? Newbie here! Any thoughts ??
👍️0
Monksdream Monksdream 6 months ago
NRSN under $2
👍️0
runncoach runncoach 6 months ago
Great data out. On to P3. Only thing that will likely sustain share price after this rally is partnership IMO.
👍️0
Awl416 Awl416 6 months ago
Don’t blink
👍️0
runncoach runncoach 8 months ago
Certainly showing a positive trend on the scientific front.
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93791685/neurosense-announces-new-positive-data-analysis-fr
👍️0
runncoach runncoach 9 months ago
Financing broke the stock for now. Either Biogen news or dead money IMO
👍️0
runncoach runncoach 9 months ago
Looks like there will be a data presentation on the sixteenth at a conference. Back in for a gamble at 1.70.
👍️0
runncoach runncoach 9 months ago
And there's the money raise at 1.50
👍️0

Your Recent History

Delayed Upgrade Clock